Heart failure (HF) is a worldwide epidemic and one of the challenges faced by the healthcare system of all nations.3 Empagliflozin is a new class of drug that has been approved for the management of all patients with symptomatic HF.4 Empagliflozin is also the first among SGLT2 inhibitors to show beneficial effects in all HF subtypes.4 Data from clinical trials have shown that empagliflozin at doses of 10 mg and 25 mg is well tolerated.5 The gene discussed is SLC5A2; the disease is hydrops fetalis.